News

The FDA will review Xolair in children from six through 11 years for the treatment of moderate to severe persistent asthma in those patients with a positive skin

Approximately 7.5 million people in the U.S. are diagnosed with some form of psoriasis, a chronic immune-mediated skin disorder presenting with varying symptoms and levels of severity. Based

Emtricitabine and tenofovir alafenamide are from Gilead Sciences, while rilpivirine is from Janssen Sciences Ireland UC. Odefsey is Gilead’s second TAF-based regimen to secure FDA approval and represents

ProStrakan agreed to pay AstraZeneca $70m upfront for the rights in the European Union as well as Iceland, Norway, Switzerland, and Liechtenstein. AstraZeneca will also receive future tiered

The guidance addresses donation of HCT/Ps from both living and deceased donors, including donors of umbilical cord blood, placenta, or other gestational tissues. The new guidance is a

The results from this study confirmed CTP-656’s superior pharmacokinetic profile to Kalydeco as was previously reported from Concert’s single ascending dose trial, which demonstrated favorable pharmacokinetic properties with

The LAVOLTA I-II studies were identical, double-blind, randomised, multicentre, placebo-controlled studies that evaluated the efficacy and safety of lebrikizumab in people with severe asthma. LAVOLTA I met its

RespireRx plans to start a phase 2A clinical trial by the end of this month to confirm the ability of CX1739 to antagonize the respiratory depressant effects of

The trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma failed to hit its primary target. AstraZeneca senior vice president, head of